The use of Nolvadex in the treatment of generic Tamoxifen-associated small joint arthralgia

Breast

Volumn 19, Issue 3, 2010, Pages 243-245

  Blencowe, N S ^a   Reichl, C ^a   Gahir, J ^a   Paterson, I ^a  

^a SOLIHULL HOSPITAL   (United Kingdom)

Author keywords

Arthralgia; Hormone treatment; Side effects; Tamoxifen

Indexed keywords

ESTROGEN RECEPTOR; TAMOXIFEN; TAMOXIFEN CITRATE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; GENERIC DRUG;

ARTHRALGIA; ARTICLE; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PREVALENCE; PRIORITY JOURNAL; ADULT; AGED; BREAST NEOPLASMS; CHEMICALLY INDUCED; COHORT ANALYSIS; COMPARATIVE STUDY; DOUBLE BLIND PROCEDURE; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; ARTHRALGIA; BREAST NEOPLASMS; COHORT STUDIES; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUGS, GENERIC; FEMALE; HUMANS; MIDDLE AGED; PREVALENCE; TAMOXIFEN; TREATMENT OUTCOME;

EID: 77953356763     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2010.02.004     Document Type: Article

References (18)

1. Goetz M.P., Kamal A., Ames M. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response. Clin Pharmacol Ther 2008, 83:160-166.
2. Perez E.A. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone responsive early breast cancer. Ann Oncol 2007 Sep 18, viii(Suppl. 8):26-35.
3. Harbeck N., Haidinger R. The patient experience. Breast Cancer Res Treat 2007, 105:91-103.
4. Cella D., Fallowfield L.J. Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy. Breast Cancer Res Treat 2008, 107:167-180.
5. Tan AL, Emery P. Role of oestrogen in the development of joint symptoms? Lancet Oncol. 9:817-818.
6. Sestak I., Cuzick J., Sapunar F., et al. Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol 2008, 9:866-872.
7. Crew D., Apollo A., Greenlee H., et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 2007 Sep 1, 25(25):3797-3799.
8. Thorne C. Management of arthralgias associated with aromatase inhibitor therapy. Curr Oncol 2007 Dec, 14(Suppl. 1):S11-S19.
9. Burnstein H.J. Aromatase inhibitor-associated arthralgia syndrome. Breast 2007 Jun, 16(3):223-234.
10. Coleman R.E., Botten W.W., Lansdown M., et al. Aromatase inhibitor-related arthralgia: clinical experience and treatment recommendations. Cancer Treat Rev 2008, 34(3):275-282.
11. Powles T.J., Hickish T., Kanis J.A., Tidy A., Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996, 14:78-84.
12. Tsai C.L., Liu T.K. Inhibition of oestradiol-induced early osteoarthritic changes by Tamoxifen. Life Sci. 1999, 50(25):1943-1951.
13. Cuzick J., Forbes J.F., Sestak I., et al. Long-term results of tamoxifen prophylaxis for breast cancer-96 month follow-up of the randomised IBIS-I trial. J Natl Cancer Inst 2007, 99:272-282.
14. Powles T.J., Ashley S., Tidy A., Smith I.E., Dowsett M. Twenty-year follow-up of the royal marsden randomised, double-blinded Tamoxifen breast cancer prevention trial. J Natl Cancer Inst 2007, 99:283-290.
15. Gerreau J.R., DeLaMelena T., Walts D., Karamlou K., Johnson N. Side effects of aromatase inhibitors versus tamoxifen: the patients' perspective. Am J Surg 2006, 192:496-498.
16. Partridge A.H., LaFountain A., Meyer E., Taylor B.S., Winer E., Asnis-Alibozek A. Adherence to initial adjuvant anastrazole therapy amongst women with early-stage breast cancer. J Clin Oncol 2008 Feb 1, 26(4):556-562.
17. Barron T.I., Connolly R., Bennett K., Feely J., Kennedy J. Early discontinuation of tamoxifen: a lesson to oncologists. Cancer 2007 Mar 1, 109(5):832-839.
18. Lash T.L., Fox M.P., Westrup J.L., Fink A.K., Silliman R. Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat 2006 Sep, 99(2):215-220.